Sulfone [EPC]

Sulfone [EPC] was reported 10881 times

Drugs of the Sulfone [EPC] class are most commonly taken among patients reporting these side effects:

# Drug class Count Frequency
0 ANAEMIA HEINZ BODY 7 0.4667
1 TYPE 1 LEPRA REACTION 17 0.3333
2 TYPE 2 LEPRA REACTION 49 0.2620
3 METHAEMOGLOBINAEMIA 499 0.2154
4 BLOOD METHAEMOGLOBIN PRESENT 20 0.1802
5 LEPROMATOUS LEPROSY 15 0.1765
6 HIV ASSOCIATED NEPHROPATHY 8 0.1569
7 TUBERCULOID LEPROSY 9 0.1385
8 MUCOCUTANEOUS LEISHMANIASIS 8 0.0656
9 AEROMONAS INFECTION 12 0.0635
10 DERMATITIS HERPETIFORMIS 14 0.0574
11 ALOPECIA SCARRING 10 0.0546
12 SERUM AMYLOID A PROTEIN INCREASED 8 0.0516
13 LEPROSY 9 0.0433
14 LEUKAEMOID REACTION 11 0.0423
15 LINEAR IGA DISEASE 63 0.0378
16 AUTOINFLAMMATORY DISEASE 8 0.0377
17 CHRONIC SPONTANEOUS URTICARIA 35 0.0302
18 ZYGOMYCOSIS 14 0.0299
19 CYANOSIS CENTRAL 7 0.0269
20 IDIOPATHIC PNEUMONIA SYNDROME 8 0.0268
21 PLEOCYTOSIS 15 0.0258
22 VANISHING BILE DUCT SYNDROME 28 0.0251
23 ANTINEUTROPHIL CYTOPLASMIC ANTIBODY POSITIVE 17 0.0232
24 HAEMOLYTIC ANAEMIA 172 0.0192
25 URTICARIAL VASCULITIS 10 0.0189
26 IMMUNE RECONSTITUTION SYNDROME 23 0.0178
27 SKIN CANDIDA 9 0.0172
28 DISSEMINATED CRYPTOCOCCOSIS 13 0.0172
29 KAPOSI'S SARCOMA 8 0.0159
30 DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS 399 0.0155
31 JARISCH-HERXHEIMER REACTION 11 0.0154
32 NOCARDIOSIS 39 0.0152
33 PYODERMA GANGRENOSUM 54 0.0150
34 TOXOPLASMOSIS 15 0.0139
35 PNEUMONIA PSEUDOMONAL 21 0.0137
36 STEROID DEPENDENCE 12 0.0137
37 CENTRAL OBESITY 10 0.0135
38 MARROW HYPERPLASIA 9 0.0132
39 COMPUTERISED TOMOGRAM THORAX ABNORMAL 9 0.0131
40 CEREBRAL ASPERGILLOSIS 8 0.0130
41 CORNEAL PERFORATION 8 0.0127
42 MYCOBACTERIUM AVIUM COMPLEX INFECTION 34 0.0127
43 CRYOGLOBULINAEMIA 9 0.0126
44 CUSHINGOID 39 0.0121
45 LUNG TRANSPLANT REJECTION 8 0.0121
46 GRANULOMATOUS LIVER DISEASE 8 0.0114
47 FLUID IMBALANCE 8 0.0114
48 SUPERINFECTION BACTERIAL 9 0.0113
49 MYCOBACTERIUM ABSCESSUS INFECTION 8 0.0112
50 HAEMOLYSIS 85 0.0110
51 PRODUCT DELIVERY MECHANISM ISSUE 59 0.0110
52 LUPUS NEPHRITIS 20 0.0107
53 CHRONIC MYELOMONOCYTIC LEUKAEMIA 7 0.0106
54 BRAIN ABSCESS 26 0.0103
55 CEREBRAL TOXOPLASMOSIS 9 0.0096
56 EOSINOPHILIC MYOCARDITIS 7 0.0096
57 CYTOMEGALOVIRUS TEST POSITIVE 17 0.0095
58 LYMPHADENITIS 23 0.0095
59 ACUTE FEBRILE NEUTROPHILIC DERMATOSIS 22 0.0095
60 BONE DEMINERALISATION 10 0.0094
61 PULMONARY CAVITATION 8 0.0092
62 ANTICOAGULATION DRUG LEVEL BELOW THERAPEUTIC 7 0.0091
63 THERAPEUTIC PRODUCT CROSS-REACTIVITY 8 0.0090
64 INFECTION REACTIVATION 10 0.0087
65 PEMPHIGOID 65 0.0086
66 URINARY TRACT INFECTION ENTEROCOCCAL 8 0.0086
67 NECROTISING FASCIITIS 30 0.0085
68 CHRONIC KIDNEY DISEASE-MINERAL AND BONE DISORDER 9 0.0085
69 PNEUMONIA CRYPTOCOCCAL 8 0.0085
70 LYMPHOCYTIC INFILTRATION 8 0.0079
71 CYTOMEGALOVIRUS VIRAEMIA 35 0.0079
72 DIFFUSE ALVEOLAR DAMAGE 9 0.0078
73 ANAEMIA OF CHRONIC DISEASE 7 0.0077
74 CUTANEOUS LUPUS ERYTHEMATOSUS 15 0.0077
75 ACCIDENTAL POISONING 10 0.0073
76 HEPATORENAL SYNDROME 12 0.0071
77 GRAFT VERSUS HOST DISEASE 49 0.0068
78 BONE MARROW TOXICITY 8 0.0068
79 WOUND COMPLICATION 23 0.0067
80 ANAEMIA MACROCYTIC 14 0.0066
81 KLEBSIELLA INFECTION 33 0.0065
82 VIRAEMIA 9 0.0065
83 TYPE 1 DIABETES MELLITUS 39 0.0065
84 MENINGITIS ASEPTIC 29 0.0065
85 EYELID IRRITATION 16 0.0064
86 HIDRADENITIS 58 0.0064
87 PLATELET TRANSFUSION 8 0.0062
88 REBOUND EFFECT 70 0.0062
89 SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS 11 0.0062
90 JUGULAR VEIN THROMBOSIS 11 0.0062
91 PNEUMONIA CYTOMEGALOVIRAL 12 0.0062
92 NORMOCYTIC ANAEMIA 9 0.0061
93 PNEUMOMEDIASTINUM 11 0.0061
94 BLOOD PRESSURE SYSTOLIC ABNORMAL 15 0.0061
95 STEROID DIABETES 9 0.0060
96 CALCIPHYLAXIS 11 0.0060
97 PRODUCT PHYSICAL CONSISTENCY ISSUE 33 0.0060
98 PSEUDOMONAS INFECTION 51 0.0059
99 STAPHYLOCOCCAL BACTERAEMIA 25 0.0057
100 HEPATITIS FULMINANT 17 0.0057
101 FANCONI SYNDROME ACQUIRED 10 0.0057
102 ACUTE GRAFT VERSUS HOST DISEASE IN INTESTINE 8 0.0057
103 WOUND SECRETION 22 0.0056
104 HYDRONEPHROSIS 42 0.0056
105 CD4 LYMPHOCYTES DECREASED 12 0.0056
106 SKIN ODOUR ABNORMAL 22 0.0056
107 STRONGYLOIDIASIS 9 0.0056
108 AUTOIMMUNE HAEMOLYTIC ANAEMIA 19 0.0055
109 NEURITIS 8 0.0052
110 PSEUDOMONAL SEPSIS 9 0.0051
111 CYTOMEGALOVIRUS CHORIORETINITIS 10 0.0051
112 SKIN HYPOPIGMENTATION 9 0.0051
113 PNEUMOCYSTIS JIROVECII PNEUMONIA 51 0.0051
114 PUSTULE 12 0.0051
115 INDURATION 9 0.0050
116 JC VIRUS INFECTION 8 0.0050
117 MYOPATHY 43 0.0050
118 GRANULOMA 17 0.0049
119 SKIN INDURATION 10 0.0048
120 EPSTEIN-BARR VIRUS INFECTION 30 0.0048
121 SUBCUTANEOUS ABSCESS 23 0.0048
122 APRAXIA 7 0.0047
123 ESCHERICHIA BACTERAEMIA 11 0.0047
124 BLOOD AMYLASE INCREASED 8 0.0047
125 THERAPEUTIC PRODUCT INEFFECTIVE 18 0.0047
126 APLASIA PURE RED CELL 16 0.0046
127 MYCOBACTERIAL INFECTION 8 0.0046
128 LUNG INFILTRATION 40 0.0045
129 AREFLEXIA 12 0.0045
130 GLOMERULONEPHRITIS 11 0.0045
131 APPLICATION SITE DISCOLOURATION 18 0.0044
132 STEM CELL TRANSPLANT 11 0.0044
133 TREATMENT FAILURE 364 0.0044
134 CYTOMEGALOVIRUS INFECTION 73 0.0044
135 KIDNEY TRANSPLANT REJECTION 21 0.0044
136 ESSENTIAL HYPERTENSION 8 0.0044
137 LUNG ABSCESS 9 0.0043
138 LUNG CONSOLIDATION 12 0.0043
139 BONE MARROW TRANSPLANT 8 0.0042
140 ECONOMIC PROBLEM 63 0.0042
141 BK VIRUS INFECTION 14 0.0041
142 PRODUCT INEFFECTIVE FOR UNAPPROVED USE 11 0.0041
143 GLUCOSE TOLERANCE IMPAIRED 24 0.0041
144 ANHEDONIA 106 0.0040
145 BRONCHOPULMONARY ASPERGILLOSIS 31 0.0040
146 THERAPY PARTIAL RESPONDER 62 0.0040
147 HYPOXIA 138 0.0039
148 CYTOMEGALOVIRUS COLITIS 9 0.0039
149 RENAL TRANSPLANT 14 0.0039
150 DRUG INEFFECTIVE FOR UNAPPROVED INDICATION 212 0.0039
151 BLOOD HIV RNA INCREASED 7 0.0039
152 APPLICATION SITE DRYNESS 13 0.0038
153 PARADOXICAL DRUG REACTION 14 0.0038
154 ADENOVIRUS INFECTION 11 0.0038
155 HYPOVOLAEMIA 22 0.0038
156 GRAFT VERSUS HOST DISEASE IN GASTROINTESTINAL TRACT 8 0.0038
157 ENTEROCOCCAL INFECTION 18 0.0037
158 LYMPHOCYTOSIS 8 0.0037
159 IMMUNE THROMBOCYTOPENIA 17 0.0037
160 NEPHROGENIC ANAEMIA 17 0.0037
161 HENOCH-SCHONLEIN PURPURA 8 0.0037
162 ACNE CYSTIC 11 0.0036
163 GRAFT VERSUS HOST DISEASE IN SKIN 8 0.0036
164 DERMATITIS EXFOLIATIVE 18 0.0036
165 HYPERPARATHYROIDISM SECONDARY 9 0.0036
166 RENAL TUBULAR NECROSIS 35 0.0036
167 END STAGE RENAL DISEASE 65 0.0036
168 CUTANEOUS VASCULITIS 13 0.0036
169 COMPLICATIONS OF TRANSPLANTED KIDNEY 8 0.0035
170 DISSEMINATED TUBERCULOSIS 9 0.0035
171 ASPERGILLUS INFECTION 23 0.0035
172 SKIN PAPILLOMA 14 0.0035
173 DERMATITIS EXFOLIATIVE GENERALISED 12 0.0034
174 CYANOSIS 54 0.0034
175 CLOSTRIDIUM DIFFICILE COLITIS 36 0.0034
176 ALANINE AMINOTRANSFERASE ABNORMAL 7 0.0033
177 NEPHROGENIC SYSTEMIC FIBROSIS 10 0.0033
178 BLOOD PHOSPHORUS INCREASED 9 0.0033
179 OSTEOPENIA 50 0.0033
180 PAPULE 23 0.0033
181 SKIN HYPERPIGMENTATION 28 0.0033
182 AZOTAEMIA 13 0.0033
183 DRUG-INDUCED LIVER INJURY 102 0.0032
184 SYNOVIAL CYST 15 0.0032
185 VENOOCCLUSIVE DISEASE 8 0.0032
186 SYSTEMIC CANDIDA 8 0.0032
187 ESCHERICHIA INFECTION 26 0.0032
188 PLATELET COUNT ABNORMAL 19 0.0031
189 CHEILITIS 17 0.0031
190 CHRONIC GASTRITIS 7 0.0031
191 HEPATITIS TOXIC 8 0.0031
192 PNEUMONIA FUNGAL 12 0.0030
193 BLOOD CULTURE POSITIVE 9 0.0030
194 NEPHRITIS 10 0.0030
195 LEUKOENCEPHALOPATHY 11 0.0030
196 CYTOMEGALOVIRUS INFECTION REACTIVATION 13 0.0029
197 NEUTROPENIC SEPSIS 21 0.0029
198 PANCYTOPENIA 163 0.0029
199 BONE MARROW FAILURE 59 0.0029
200 DERMATITIS BULLOUS 21 0.0029
201 BLOOD CREATININE ABNORMAL 10 0.0029
202 ENCEPHALITIS 20 0.0029
203 NECROSIS 16 0.0029
204 THERAPY NON-RESPONDER 129 0.0029
205 LUPUS-LIKE SYNDROME 26 0.0029
206 ACUTE RESPIRATORY FAILURE 55 0.0029
207 RASH MACULO-PAPULAR 63 0.0028
208 RHINOVIRUS INFECTION 11 0.0028
209 ORAL CANDIDIASIS 37 0.0028
210 PURULENT DISCHARGE 12 0.0028
211 HYPERBILIRUBINAEMIA 29 0.0028
212 BLOOD ALBUMIN DECREASED 22 0.0028
213 SKIN LESION 76 0.0028
214 BACTERIAL SEPSIS 9 0.0028
215 LYMPHOCYTE COUNT INCREASED 9 0.0028
216 BLOOD PRESSURE DIASTOLIC ABNORMAL 7 0.0027
217 SKIN PLAQUE 23 0.0027
218 PRE-EXISTING CONDITION IMPROVED 17 0.0027
219 SEBORRHOEA 10 0.0027
220 LYME DISEASE 9 0.0027
221 HEPATITIS B 16 0.0027
222 HEPATIC NECROSIS 10 0.0027
223 HIV INFECTION 8 0.0027
224 ONYCHOMADESIS 11 0.0026
225 HAEMODIALYSIS 22 0.0026
226 OESOPHAGEAL ULCER 10 0.0026
227 MULTIPLE-DRUG RESISTANCE 8 0.0026
228 ULCER 41 0.0026
229 HEPATOMEGALY 25 0.0025
230 LEUKOCYTOSIS 46 0.0025
231 FOREIGN BODY IN THROAT 8 0.0025
232 OCULAR ICTERUS 11 0.0025
233 ACUTE GRAFT VERSUS HOST DISEASE IN SKIN 7 0.0025
234 SKIN NECROSIS 13 0.0025
235 CANDIDIASIS 10 0.0025
236 UROSEPSIS 23 0.0025
237 CHRONIC GRAFT VERSUS HOST DISEASE 9 0.0025
238 SQUAMOUS CELL CARCINOMA OF SKIN 15 0.0025
239 DRUG RASH WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS 8 0.0025
240 PLASMA CELL MYELOMA RECURRENT 8 0.0025
241 HERPES SIMPLEX 16 0.0025
242 SEROTONIN SYNDROME 47 0.0024
243 ANGIOEDEMA 107 0.0024
244 DRUG LEVEL ABOVE THERAPEUTIC 11 0.0024
245 PEMPHIGUS 30 0.0024
246 HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS 18 0.0024
247 PROTEIN TOTAL DECREASED 9 0.0024
248 CLOSTRIDIAL INFECTION 8 0.0024
249 THROMBOTIC MICROANGIOPATHY 23 0.0024
250 BLOOD PRESSURE SYSTOLIC INCREASED 46 0.0024
251 APHTHOUS ULCER 18 0.0023
252 FIBROSIS 7 0.0023
253 BRONCHIOLITIS 8 0.0023
254 OESOPHAGEAL CANDIDIASIS 9 0.0023
255 COELIAC DISEASE 22 0.0022
256 QUALITY OF LIFE DECREASED 30 0.0022
257 JAUNDICE 60 0.0022
258 APPLICATION SITE EXFOLIATION 9 0.0022
259 PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY 18 0.0022
260 HAEMOGLOBIN ABNORMAL 14 0.0022
261 PULMONARY HAEMORRHAGE 17 0.0022
262 TOXIC EPIDERMAL NECROLYSIS 33 0.0022
263 GASTRIC ULCER HAEMORRHAGE 12 0.0022
264 CLOSTRIDIUM DIFFICILE INFECTION 47 0.0022
265 DERMATITIS 45 0.0021
266 ROSACEA 10 0.0021
267 MULTIPLE MYELOMA 10 0.0021
268 BLOOD LACTATE DEHYDROGENASE INCREASED 34 0.0021
269 NODULE 28 0.0021
270 OSTEOPOROSIS 88 0.0021
271 ABSCESS 34 0.0021
272 STAPHYLOCOCCAL INFECTION 70 0.0021
273 TRANSPLANT REJECTION 17 0.0021
274 FAILURE TO THRIVE 11 0.0021
275 SEPSIS 236 0.0021
276 BASAL CELL CARCINOMA 33 0.0021
277 BLOOD CREATININE INCREASED 137 0.0021
278 CYST 26 0.0021
279 OXYGEN SATURATION DECREASED 116 0.0021
280 VIRAL LOAD INCREASED 8 0.0021
281 VASCULITIS 24 0.0021
282 HYPERTRIGLYCERIDAEMIA 12 0.0020
283 BACTERAEMIA 24 0.0020
284 HYDROCEPHALUS 11 0.0020
285 PETECHIAE 21 0.0020
286 DISEASE RECURRENCE 95 0.0020
287 SCAR 34 0.0020
288 LEUKOPENIA 99 0.0020
289 ANAEMIA 376 0.0020
290 PRODUCT FORMULATION ISSUE 13 0.0020
291 STEVENS-JOHNSON SYNDROME 43 0.0019
292 BLOOD BILIRUBIN INCREASED 52 0.0019
293 BLOOD PHOSPHORUS DECREASED 7 0.0019
294 HEPATITIS 49 0.0019
295 SKIN TIGHTNESS 9 0.0019
296 SQUAMOUS CELL CARCINOMA 18 0.0019
297 FEBRILE NEUTROPENIA 126 0.0019
298 CHRONIC LYMPHOCYTIC LEUKAEMIA 9 0.0019
299 POLYARTHRITIS 10 0.0019
300 PHOTOSENSITIVITY REACTION 31 0.0019
301 MENTAL STATUS CHANGES 52 0.0019
302 PRODUCT CONTAINER ISSUE 16 0.0019
303 OSTEONECROSIS 61 0.0019
304 CHRONIC KIDNEY DISEASE 140 0.0018
305 INTERVERTEBRAL DISC DEGENERATION 17 0.0018
306 ACIDOSIS 14 0.0018
307 AGRANULOCYTOSIS 34 0.0018
308 HYPOGAMMAGLOBULINAEMIA 12 0.0018
309 ERYTHEMA MULTIFORME 17 0.0018
310 DIFFUSE LARGE B-CELL LYMPHOMA 14 0.0018
311 ADRENAL INSUFFICIENCY 22 0.0018
312 ACUTE RESPIRATORY DISTRESS SYNDROME 32 0.0018
313 IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME 9 0.0018
314 DRUG ERUPTION 32 0.0018
315 SKIN MASS 12 0.0018
316 STREPTOCOCCAL INFECTION 10 0.0018
317 DRUG RESISTANCE 46 0.0018
318 CARPAL TUNNEL SYNDROME 25 0.0018
319 TORSADE DE POINTES 14 0.0018
320 SUSPECTED OFF LABEL USE 8 0.0018
321 RENAL FAILURE ACUTE 75 0.0018
322 HAEMATOCRIT DECREASED 35 0.0018
323 THROMBOCYTOPENIA 197 0.0018
324 DECREASED ACTIVITY 19 0.0018
325 BLOOD PRESSURE SYSTOLIC DECREASED 8 0.0018
326 RENAL FAILURE 233 0.0018
327 CEREBRAL ISCHAEMIA 9 0.0017
328 RED BLOOD CELL COUNT DECREASED 50 0.0017
329 BLOOD DISORDER 14 0.0017
330 CYTOKINE RELEASE SYNDROME 35 0.0017
331 HERPES VIRUS INFECTION 10 0.0017
332 ENURESIS 7 0.0017
333 WHITE BLOOD CELL COUNT ABNORMAL 11 0.0017
334 APLASTIC ANAEMIA 9 0.0017
335 ARTHRITIS BACTERIAL 7 0.0017
336 PHOTOPHOBIA 32 0.0017
337 LYMPHADENOPATHY 60 0.0017
338 FACIAL PAIN 15 0.0017
339 GANGRENE 10 0.0017
340 RESPIRATORY FAILURE 121 0.0017
341 FOETAL GROWTH RESTRICTION 10 0.0016
342 LYMPHOPENIA 23 0.0016
343 BLOOD PRESSURE DIASTOLIC DECREASED 12 0.0016
344 PANCREATIC DISORDER 8 0.0016
345 RENAL IMPAIRMENT 136 0.0016
346 DRUG TOXICITY 22 0.0016
347 BLOOD UREA INCREASED 27 0.0016
348 SCRATCH 17 0.0016
349 GINGIVAL BLEEDING 22 0.0016
350 ECCHYMOSIS 11 0.0016
351 ACUTE KIDNEY INJURY 245 0.0016
352 BLOOD ALKALINE PHOSPHATASE INCREASED 39 0.0016
353 SUPRAVENTRICULAR TACHYCARDIA 15 0.0016
354 LIPASE INCREASED 12 0.0016
355 MULTI-ORGAN FAILURE 27 0.0016
356 BLISTER 87 0.0015
357 SKIN ULCER 40 0.0015
358 LIVER FUNCTION TEST ABNORMAL 45 0.0015
359 TACHYPNOEA 21 0.0015
360 APPLICATION SITE PAIN 34 0.0015
361 EOSINOPHILIA 27 0.0015
362 HEPATIC FAILURE 46 0.0015
363 BLOOD LACTIC ACID INCREASED 8 0.0015
364 MULTIPLE ORGAN DYSFUNCTION SYNDROME 43 0.0015
365 BLOOD PRESSURE DIASTOLIC INCREASED 7 0.0015
366 UPPER RESPIRATORY TRACT INFECTION 70 0.0015
367 PLASMA CELL MYELOMA 59 0.0015
368 RENAL CYST 12 0.0015
369 CELLULITIS 76 0.0015
370 PHARYNGOLARYNGEAL PAIN 8 0.0015
371 SKIN DISORDER 50 0.0015
372 OFF LABEL USE 1307 0.0015
373 RESPIRATORY DISTRESS 41 0.0015
374 HYPERKALAEMIA 52 0.0015
375 IMMUNODEFICIENCY 22 0.0015
376 IMMUNOSUPPRESSION 13 0.0015
377 ENCEPHALOPATHY 36 0.0015
378 RESPIRATORY RATE INCREASED 13 0.0015
379 FAECALOMA 8 0.0015
380 PIGMENTATION DISORDER 9 0.0015
381 SPINAL COMPRESSION FRACTURE 12 0.0014
382 SPLENOMEGALY 17 0.0014
383 OLIGURIA 9 0.0014
384 ATELECTASIS 14 0.0014
385 SKIN EXFOLIATION 122 0.0014
386 HAEMODYNAMIC INSTABILITY 11 0.0014
387 COVID-19 PNEUMONIA 17 0.0014
388 SKIN INFECTION 16 0.0014
389 SEPTIC SHOCK 62 0.0014
390 PRODUCT USE IN UNAPPROVED INDICATION 351 0.0014
391 ACUTE MYELOID LEUKAEMIA 22 0.0014
392 CHOLESTASIS 27 0.0014
393 RASH ERYTHEMATOUS 67 0.0014
394 DRUG EFFECTIVE FOR UNAPPROVED INDICATION 41 0.0014
395 FULL BLOOD COUNT DECREASED 28 0.0014
396 CYTOPENIA 17 0.0014
397 PNEUMOTHORAX 22 0.0014
398 ACNE 105 0.0014
399 RASH PAPULAR 31 0.0014
400 SMALL INTESTINAL OBSTRUCTION 17 0.0014
401 RESPIRATORY SYNCYTIAL VIRUS INFECTION 12 0.0014
402 SKIN WARM 8 0.0014
403 AMMONIA INCREASED 7 0.0014
404 PYREXIA 474 0.0014
405 GROIN PAIN 12 0.0014
406 MYASTHENIA GRAVIS 11 0.0014
407 PNEUMONITIS 37 0.0014
408 INTENTIONAL PRODUCT USE ISSUE 119 0.0014
409 HYPOPHOSPHATAEMIA 10 0.0014
410 POOR VENOUS ACCESS 14 0.0014
411 BLOOD IRON DECREASED 16 0.0013
412 MENINGITIS 9 0.0013
413 PULMONARY MASS 20 0.0013
414 BACTERIAL INFECTION 25 0.0013
415 HYPERLIPIDAEMIA 16 0.0013
416 SKIN DISCOLOURATION 61 0.0013
417 DEEP VEIN THROMBOSIS 86 0.0013
418 DERMATITIS ACNEIFORM 8 0.0013
419 FLUID OVERLOAD 19 0.0013
420 DRUG INTOLERANCE 126 0.0013
421 HEPATOTOXICITY 29 0.0013
422 PLATELET COUNT DECREASED 138 0.0013
423 CATARACT 77 0.0013
424 EMOTIONAL DISTRESS 156 0.0013
425 MENTAL DISORDER 56 0.0013
426 NEUROPATHY PERIPHERAL 122 0.0013
427 METABOLIC ACIDOSIS 41 0.0013
428 ANURIA 11 0.0013
429 HAEMOGLOBIN DECREASED 131 0.0013
430 NEUTROPENIA 173 0.0013
431 LETHARGY 73 0.0013
432 SKIN SWELLING 11 0.0013
433 EAR DISCOMFORT 13 0.0013
434 PROTEINURIA 24 0.0013
435 ASPARTATE AMINOTRANSFERASE INCREASED 67 0.0013
436 POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME 12 0.0013
437 LABORATORY TEST ABNORMAL 37 0.0013
438 MALNUTRITION 14 0.0013
439 DRUG INTERACTION 198 0.0012
440 TENDERNESS 13 0.0012
441 RASH PUSTULAR 9 0.0012
442 BLOOD POTASSIUM INCREASED 20 0.0012
443 HEPATITIS ACUTE 8 0.0012
444 VITAMIN D DEFICIENCY 12 0.0012
445 FUNGAL INFECTION 41 0.0012
446 LYMPHOMA 19 0.0012
447 ORAL DISORDER 9 0.0012
448 UPPER-AIRWAY COUGH SYNDROME 10 0.0012
449 BLOOD PRESSURE FLUCTUATION 29 0.0012
450 CONDITION AGGRAVATED 367 0.0012
451 APPLICATION SITE IRRITATION 15 0.0012
452 EOSINOPHIL COUNT INCREASED 10 0.0012
453 PLEURAL EFFUSION 73 0.0012
454 WHITE BLOOD CELL COUNT DECREASED 130 0.0012
455 WHITE BLOOD CELL COUNT INCREASED 46 0.0012
456 PNEUMONIA BACTERIAL 11 0.0012
457 PRODUCT PRESCRIBING ISSUE 26 0.0012
458 PRODUCT PHYSICAL ISSUE 24 0.0012
459 PNEUMONIA 385 0.0012
460 POSTOPERATIVE WOUND INFECTION 8 0.0012
461 MUCOSAL INFLAMMATION 31 0.0012
462 SYSTEMIC LUPUS ERYTHEMATOSUS 42 0.0012
463 EYELID PTOSIS 12 0.0012
464 RASH MACULAR 41 0.0012
465 ACUTE HEPATIC FAILURE 16 0.0012
466 EYE MOVEMENT DISORDER 8 0.0012
467 ANOREXIA 15 0.0012
468 ONYCHOCLASIS 8 0.0012
469 BLOOD MAGNESIUM DECREASED 10 0.0012
470 IMPAIRED HEALING 38 0.0012
471 HYPERGLYCAEMIA 42 0.0012
472 DELIRIUM 40 0.0012
473 NIGHT SWEATS 37 0.0011
474 COAGULOPATHY 19 0.0011
475 DERMATITIS CONTACT 13 0.0011
476 HYPERCALCAEMIA 14 0.0011
477 PURPURA 10 0.0011
478 OBESITY 18 0.0011
479 HAND FRACTURE 8 0.0011
480 NEUTROPHIL COUNT DECREASED 46 0.0011
481 RASH PRURITIC 61 0.0011
482 TRANSAMINASES INCREASED 25 0.0011
483 DIVERTICULITIS 31 0.0011
484 BONE DENSITY DECREASED 35 0.0011
485 BRAIN OEDEMA 14 0.0011
486 MUSCLE ATROPHY 14 0.0011
487 PULMONARY HYPERTENSION 23 0.0011
488 TREATMENT NONCOMPLIANCE 60 0.0011
489 GASTROENTERITIS 16 0.0011
490 MOUTH ULCERATION 23 0.0011
491 IRON DEFICIENCY ANAEMIA 10 0.0011
492 PERICARDIAL EFFUSION 25 0.0011
493 HYPOMAGNESAEMIA 15 0.0011
494 NEPHROPATHY TOXIC 12 0.0011
495 DIALYSIS 15 0.0011
496 GENERALISED OEDEMA 13 0.0010
497 DISEASE PROGRESSION 124 0.0010
498 SKIN IRRITATION 48 0.0010
499 ALANINE AMINOTRANSFERASE INCREASED 64 0.0010
500 MUSCLE STRAIN 9 0.0010
501 PAIN OF SKIN 28 0.0010
502 PYELONEPHRITIS 9 0.0010
503 DYSPNOEA EXERTIONAL 39 0.0010
504 DIZZINESS POSTURAL 10 0.0010
505 APPLICATION SITE ERYTHEMA 27 0.0010
506 HYPOALBUMINAEMIA 8 0.0010
507 AUTOIMMUNE DISORDER 10 0.0010
508 OEDEMA PERIPHERAL 125 0.0010
509 LYMPHOCYTE COUNT DECREASED 18 0.0010
510 URTICARIA 170 0.0010
511 PULMONARY EMBOLISM 96 0.0010
512 SINUS DISORDER 20 0.0010
513 ASPIRATION 11 0.0010
514 DISSEMINATED INTRAVASCULAR COAGULATION 14 0.0010
515 OSTEOMYELITIS 18 0.0010
516 NOCTURIA 12 0.0010
517 GLAUCOMA 19 0.0010
518 NO THERAPEUTIC RESPONSE 12 0.0010
519 RETINAL DETACHMENT 9 0.0010
520 FISTULA 11 0.0010
521 PERSONALITY CHANGE 9 0.0010
522 LUNG INFECTION 15 0.0010
523 EMBOLISM 8 0.0010
524 HERPES ZOSTER 55 0.0010
525 DERMATITIS ALLERGIC 12 0.0010
526 CANDIDA INFECTION 16 0.0009
527 INTERNATIONAL NORMALISED RATIO INCREASED 27 0.0009
528 CHILLS 111 0.0009
529 EYE INFLAMMATION 9 0.0009
530 PRODUCTIVE COUGH 45 0.0009
531 HAEMATURIA 32 0.0009
532 ERYTHEMA 192 0.0009
533 RASH 407 0.0009
534 HYPERTENSION 195 0.0009
535 AORTIC ANEURYSM 7 0.0009
536 LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES 44 0.0009
537 INSURANCE ISSUE 14 0.0009
538 OESOPHAGITIS 10 0.0009
539 SPINAL OSTEOARTHRITIS 8 0.0009
540 IMMUNE SYSTEM DISORDER 12 0.0009
541 VENTRICULAR TACHYCARDIA 15 0.0009
542 THERAPEUTIC RESPONSE DECREASED 55 0.0009
543 TUBULOINTERSTITIAL NEPHRITIS 17 0.0009
544 OEDEMA 49 0.0009
545 RESPIRATORY DISORDER 27 0.0009
546 FOOT DEFORMITY 10 0.0009
547 VIRAL INFECTION 30 0.0009
548 VENTRICULAR FIBRILLATION 10 0.0009
549 HYPOCALCAEMIA 17 0.0009
550 BRAIN INJURY 9 0.0009
551 LIVER INJURY 22 0.0009
552 WOUND 25 0.0009
553 CARDIOMEGALY 11 0.0009
554 GASTROINTESTINAL INFECTION 8 0.0009
555 MYOSITIS 8 0.0009
556 AFFECTIVE DISORDER 7 0.0009
557 FACE OEDEMA 15 0.0009
558 HYPOTENSION 178 0.0009
559 TASTE DISORDER 18 0.0009
560 PULMONARY FIBROSIS 17 0.0009
561 DRUG INEFFECTIVE 1167 0.0009
562 TOOTH ABSCESS 9 0.0009
563 GASTRITIS 23 0.0009
564 KIDNEY INFECTION 17 0.0009
565 BONE LOSS 13 0.0009
566 TRANSFUSION 9 0.0009
567 MASS 12 0.0009
568 LUNG DISORDER 42 0.0009
569 NEPHROPATHY 8 0.0009
570 DEHYDRATION 114 0.0009
571 BLINDNESS UNILATERAL 12 0.0008
572 ASCITES 25 0.0008
573 BLOOD TRIGLYCERIDES INCREASED 15 0.0008
574 SPINAL FRACTURE 17 0.0008
575 ADVERSE DRUG REACTION 76 0.0008
576 PLATELET COUNT INCREASED 11 0.0008
577 INFECTION 122 0.0008
578 HAEMATOTOXICITY 8 0.0008
579 LIP SWELLING 28 0.0008
580 BLOOD POTASSIUM DECREASED 25 0.0008
581 MYELODYSPLASTIC SYNDROME 12 0.0008
582 BIPOLAR DISORDER 9 0.0008
583 LOCALISED INFECTION 20 0.0008
584 SHOCK 19 0.0008
585 MENTAL IMPAIRMENT 20 0.0008
586 C-REACTIVE PROTEIN INCREASED 30 0.0008
587 ANAPHYLACTIC REACTION 45 0.0008
588 RED BLOOD CELL SEDIMENTATION RATE INCREASED 9 0.0008
589 RASH GENERALISED 21 0.0008
590 PULMONARY OEDEMA 36 0.0008
591 PANCREATITIS ACUTE 18 0.0008
592 DIABETES MELLITUS 61 0.0008
593 TACHYCARDIA 71 0.0008
594 SWELLING FACE 52 0.0008
595 BRONCHITIS 59 0.0008
596 BLOOD SODIUM DECREASED 15 0.0008
597 EMPHYSEMA 8 0.0008
598 DEPRESSED LEVEL OF CONSCIOUSNESS 31 0.0008
599 GASTROINTESTINAL DISORDER 70 0.0008
600 NEUTROPHIL COUNT INCREASED 8 0.0008
601 DEVICE RELATED INFECTION 12 0.0008
602 MOBILITY DECREASED 56 0.0008
603 HIP FRACTURE 25 0.0008
604 RENAL INJURY 23 0.0008
605 ASTHENIA 291 0.0008
606 RENAL DISORDER 36 0.0008
607 ABDOMINAL PAIN 179 0.0008
608 PARALYSIS 11 0.0008
609 CARDIOGENIC SHOCK 11 0.0008
610 FOLLICULITIS 8 0.0008
611 APHASIA 23 0.0008
612 PULMONARY CONGESTION 10 0.0008
613 SARS-COV-2 TEST POSITIVE 10 0.0008
614 INCONTINENCE 8 0.0008
615 BURNING SENSATION 53 0.0008
616 HYPOTHYROIDISM 24 0.0008
617 ORTHOSTATIC HYPOTENSION 13 0.0007
618 JOINT RANGE OF MOTION DECREASED 10 0.0007
619 HEREDITARY ANGIOEDEMA 8 0.0007
620 HEPATIC CIRRHOSIS 14 0.0007
621 NEUROTOXICITY 13 0.0007
622 NEURALGIA 18 0.0007
623 FOOT FRACTURE 14 0.0007
624 GASTRIC ULCER 14 0.0007
625 SKIN LACERATION 8 0.0007
626 DIABETES MELLITUS INADEQUATE CONTROL 13 0.0007
627 HEPATIC ENZYME INCREASED 50 0.0007
628 MULTIPLE FRACTURES 12 0.0007
629 TENDON RUPTURE 9 0.0007
630 ILEUS 9 0.0007
631 ANXIETY 206 0.0007
632 SINUSITIS 74 0.0007
633 GAMMA-GLUTAMYLTRANSFERASE INCREASED 16 0.0007
634 LIVER DISORDER 32 0.0007
635 BONE DISORDER 13 0.0007
636 BODY TEMPERATURE DECREASED 7 0.0007
637 EYE INFECTION 8 0.0007
638 SLEEP DISORDER DUE TO A GENERAL MEDICAL CONDITION 12 0.0007
639 IMPAIRED WORK ABILITY 15 0.0007
640 MICTURITION URGENCY 8 0.0007
641 BLOOD PRESSURE INCREASED 107 0.0007
642 IRRITABLE BOWEL SYNDROME 15 0.0007
643 EYE SWELLING 26 0.0007
644 INJECTION SITE REACTION 48 0.0007
645 THROMBOSIS 56 0.0007
646 DYSPNOEA 394 0.0007
647 DEPRESSION 158 0.0007
648 THERAPEUTIC RESPONSE UNEXPECTED 31 0.0007
649 EYELID OEDEMA 8 0.0007
650 WEIGHT INCREASED 154 0.0007
651 CONFUSIONAL STATE 111 0.0007
652 COLITIS 26 0.0007
653 SLEEP APNOEA SYNDROME 13 0.0007
654 PANCREATITIS 36 0.0007
655 MUSCULAR WEAKNESS 77 0.0007
656 RECTAL HAEMORRHAGE 29 0.0007
657 DRUG EFFECT LESS THAN EXPECTED 10 0.0007
658 INTENTIONAL OVERDOSE 43 0.0007
659 HAEMORRHAGE INTRACRANIAL 10 0.0007
660 EAR PAIN 13 0.0007
661 GENERALISED TONIC-CLONIC SEIZURE 11 0.0007
662 GASTROENTERITIS VIRAL 12 0.0007
663 HYPOAESTHESIA ORAL 10 0.0007
664 WEIGHT DECREASED 185 0.0007
665 LIMB INJURY 18 0.0007
666 DIARRHOEA 427 0.0007
667 IMPAIRED GASTRIC EMPTYING 9 0.0007
668 PRESYNCOPE 16 0.0007
669 HYPONATRAEMIA 37 0.0007
670 LIVER FUNCTION TEST INCREASED 14 0.0007
671 DYSURIA 24 0.0007
672 HYPOKALAEMIA 30 0.0006
673 ABNORMAL WEIGHT GAIN 8 0.0006
674 PRURITUS GENERALISED 14 0.0006
675 ANKLE FRACTURE 10 0.0006
676 GASTROOESOPHAGEAL REFLUX DISEASE 52 0.0006
677 COORDINATION ABNORMAL 9 0.0006
678 HEPATIC FUNCTION ABNORMAL 24 0.0006
679 EAR INFECTION 17 0.0006
680 SECRETION DISCHARGE 8 0.0006
681 LOWER RESPIRATORY TRACT INFECTION 29 0.0006
682 BODY TEMPERATURE INCREASED 13 0.0006
683 DENTAL CARIES 7 0.0006
684 THERAPEUTIC PRODUCT EFFECT INCOMPLETE 45 0.0006
685 PRURITUS 242 0.0006
686 FATIGUE 490 0.0006
687 CONSTIPATION 137 0.0006
688 COUGH 176 0.0006
689 PRODUCT SUBSTITUTION ISSUE 36 0.0006
690 VOMITING 293 0.0006
691 NAUSEA 492 0.0006
692 DRY EYE 31 0.0006
693 INFUSION SITE PAIN 8 0.0006
694 DIPLOPIA 16 0.0006
695 PRODUCT AVAILABILITY ISSUE 14 0.0006
696 DRY SKIN 82 0.0006
697 RESPIRATORY TRACT INFECTION 16 0.0006
698 PAIN 377 0.0006
699 GENERAL PHYSICAL HEALTH DETERIORATION 71 0.0006
700 BLINDNESS 25 0.0006
701 NO ADVERSE EVENT 111 0.0006
702 DECREASED APPETITE 142 0.0006
703 CARDIAC FAILURE 49 0.0006
704 SWELLING 57 0.0006
705 SKIN HAEMORRHAGE 9 0.0006
706 ATRIAL FIBRILLATION 59 0.0006
707 DISORIENTATION 24 0.0006
708 CHEST PAIN 112 0.0006
709 INAPPROPRIATE SCHEDULE OF DRUG ADMINISTRATION 43 0.0006
710 URINARY TRACT INFECTION 103 0.0006
711 ADVERSE REACTION 8 0.0006
712 ELECTROLYTE IMBALANCE 7 0.0006
713 AMNESIA 39 0.0006
714 PERIPHERAL SWELLING 92 0.0006
715 CYSTITIS 19 0.0006
716 CONVULSION 34 0.0006
717 BLOOD COUNT ABNORMAL 9 0.0006
718 CONTUSION 57 0.0006
719 INFUSION RELATED REACTION 39 0.0006
720 HYPOPHAGIA 15 0.0006
721 TOOTH DISORDER 13 0.0006
722 INFLUENZA 65 0.0006
723 UNRESPONSIVE TO STIMULI 15 0.0006
724 BRAIN FOG 9 0.0006
725 MUSCLE SPASMS 105 0.0006
726 BLOOD TEST ABNORMAL 8 0.0006
727 RESPIRATORY TRACT CONGESTION 9 0.0006
728 SEASONAL ALLERGY 8 0.0006
729 PRODUCT DOSE OMISSION ISSUE 166 0.0006
730 CORONARY ARTERY DISEASE 17 0.0006
731 HYPERSENSITIVITY 104 0.0006
732 MYALGIA 95 0.0006
733 DRUG EXPOSURE DURING PREGNANCY 19 0.0006
734 DYSPHAGIA 53 0.0006
735 INTERSTITIAL LUNG DISEASE 27 0.0006
736 LACTIC ACIDOSIS 18 0.0006
737 VISION BLURRED 76 0.0006
738 PRODUCT USE ISSUE 104 0.0006
739 TOOTHACHE 10 0.0006
740 PALLOR 15 0.0006
741 DYSSTASIA 16 0.0005
742 OSTEOARTHRITIS 23 0.0005
743 PSYCHOTIC DISORDER 16 0.0005
744 CARDIOMYOPATHY 8 0.0005
745 SUICIDAL IDEATION 49 0.0005
746 TYPE 2 DIABETES MELLITUS 18 0.0005
747 MOOD SWINGS 17 0.0005
748 CARDIAC ARREST 44 0.0005
749 FLUID RETENTION 27 0.0005
750 OCULAR HYPERAEMIA 25 0.0005
751 BLOOD PRESSURE DECREASED 35 0.0005
752 ABASIA 13 0.0005
753 HAEMATOCHEZIA 29 0.0005
754 EYE HAEMORRHAGE 7 0.0005
755 NEPHROLITHIASIS 24 0.0005
756 DRUG EFFECT INCOMPLETE 19 0.0005
757 PARANOIA 9 0.0005
758 POST PROCEDURAL COMPLICATION 10 0.0005
759 MUSCULOSKELETAL CHEST PAIN 8 0.0005
760 SKIN BURNING SENSATION 37 0.0005
761 LOCAL SWELLING 9 0.0005
762 HYPOGLYCAEMIA 25 0.0005
763 PRODUCT QUALITY ISSUE 70 0.0005
764 GASTROINTESTINAL HAEMORRHAGE 43 0.0005
765 HEART RATE DECREASED 18 0.0005
766 SKIN FISSURES 10 0.0005
767 SKIN CANCER 11 0.0005
768 APPLICATION SITE RASH 7 0.0005
769 BACK PAIN 118 0.0005
770 ACTIVITIES OF DAILY LIVING IMPAIRED 10 0.0005
771 ASTHMA 57 0.0005
772 ISCHAEMIC STROKE 9 0.0005
773 PALPITATIONS 59 0.0005
774 THIRST 9 0.0005
775 HAEMOPTYSIS 14 0.0005
776 APHONIA 7 0.0005
777 HYPOAESTHESIA 75 0.0005
778 PREGNANCY 10 0.0005
779 TOXICITY TO VARIOUS AGENTS 84 0.0005
780 ECZEMA 26 0.0005
781 GASTRIC DISORDER 17 0.0005
782 STOMATITIS 30 0.0005
783 EPISTAXIS 37 0.0005
784 ILL-DEFINED DISORDER 30 0.0005
785 BLOOD CHOLESTEROL INCREASED 23 0.0005
786 HEADACHE 308 0.0005
787 COVID-19 86 0.0005
788 WHEEZING 29 0.0005
789 RIB FRACTURE 10 0.0005
790 INFLAMMATION 25 0.0005
791 DRUG LEVEL INCREASED 8 0.0005
792 HEPATIC STEATOSIS 9 0.0005
793 TREMOR 80 0.0005
794 SYNCOPE 48 0.0005
795 GAIT INABILITY 16 0.0005
796 MOOD ALTERED 13 0.0005
797 NASAL CONGESTION 28 0.0005
798 GAIT DISTURBANCE 91 0.0005
799 ACUTE MYOCARDIAL INFARCTION 14 0.0005
800 ABDOMINAL PAIN LOWER 12 0.0005
801 FEELING HOT 29 0.0005
802 HEMIPARESIS 8 0.0005
803 MYELOSUPPRESSION 17 0.0005
804 ABDOMINAL DISTENSION 49 0.0005
805 HERNIA 9 0.0005
806 HAEMATOMA 12 0.0005
807 UNEVALUABLE EVENT 35 0.0005
808 HOSPITALISATION 71 0.0005
809 COMA 22 0.0005
810 DIABETIC KETOACIDOSIS 11 0.0005
811 PARAESTHESIA 72 0.0005
812 INTERVERTEBRAL DISC PROTRUSION 10 0.0005
813 CHOLELITHIASIS 15 0.0005
814 INTENTIONAL DOSE OMISSION 13 0.0005
815 OROPHARYNGEAL PAIN 42 0.0005
816 UPPER LIMB FRACTURE 9 0.0005
817 DYSARTHRIA 17 0.0005
818 DIZZINESS 225 0.0005
819 COGNITIVE DISORDER 21 0.0004
820 INJECTION SITE URTICARIA 11 0.0004
821 FEELING ABNORMAL 107 0.0004
822 GOUT 8 0.0004
823 SUICIDE ATTEMPT 27 0.0004
824 LOSS OF CONSCIOUSNESS 57 0.0004
825 HEART RATE INCREASED 44 0.0004
826 CHROMATURIA 10 0.0004
827 ABDOMINAL DISCOMFORT 74 0.0004
828 SLEEP DISORDER 31 0.0004
829 URINARY INCONTINENCE 13 0.0004
830 MALAISE 192 0.0004
831 INFLUENZA LIKE ILLNESS 36 0.0004
832 CARDIAC FAILURE CONGESTIVE 35 0.0004
833 DEPRESSED MOOD 23 0.0004
834 TOOTH LOSS 9 0.0004
835 MUSCULOSKELETAL STIFFNESS 38 0.0004
836 CONJUNCTIVITIS 8 0.0004
837 CARDIO-RESPIRATORY ARREST 18 0.0004
838 HAEMORRHAGE 45 0.0004
839 BALANCE DISORDER 37 0.0004
840 ILLNESS 44 0.0004
841 INSOMNIA 113 0.0004
842 PRODUCT DOSE OMISSION IN ERROR 12 0.0004
843 THROAT IRRITATION 19 0.0004
844 VISUAL ACUITY REDUCED 14 0.0004
845 MUSCULOSKELETAL PAIN 22 0.0004
846 URINARY RETENTION 14 0.0004
847 CEREBRAL HAEMORRHAGE 15 0.0004
848 INCREASED APPETITE 8 0.0004
849 HYPERSOMNIA 12 0.0004
850 EXPOSURE DURING PREGNANCY 26 0.0004
851 DERMATITIS ATOPIC 22 0.0004
852 BLOOD CREATINE PHOSPHOKINASE INCREASED 12 0.0004
853 FIBROMYALGIA 10 0.0004
854 MELAENA 9 0.0004
855 FALL 136 0.0004
856 POLLAKIURIA 17 0.0004
857 FLATULENCE 23 0.0004
858 INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION 73 0.0004
859 DISABILITY 8 0.0004
860 OSTEONECROSIS OF JAW 10 0.0004
861 ARTHRALGIA 168 0.0004
862 NASOPHARYNGITIS 74 0.0004
863 SNEEZING 9 0.0004
864 PRODUCT DOSE OMISSION 26 0.0004
865 APPLICATION SITE PRURITUS 9 0.0004
866 MUSCLE TWITCHING 9 0.0004
867 EMOTIONAL DISORDER 12 0.0004
868 MIGRAINE 37 0.0004
869 ALOPECIA 76 0.0004
870 EYE IRRITATION 22 0.0004
871 ARTHROPATHY 21 0.0004
872 NIGHTMARE 13 0.0004
873 BONE PAIN 22 0.0004
874 ABORTION SPONTANEOUS 15 0.0004
875 FEAR 10 0.0004
876 VISUAL IMPAIRMENT 46 0.0004
877 TINNITUS 17 0.0004
878 THROAT TIGHTNESS 10 0.0004
879 BLOOD URINE PRESENT 7 0.0004
880 FEELING JITTERY 7 0.0004
881 INTENTIONAL PRODUCT MISUSE 32 0.0004
882 LACRIMATION INCREASED 11 0.0004
883 SOMNOLENCE 73 0.0004
884 CHEST DISCOMFORT 37 0.0004
885 EXPIRED PRODUCT ADMINISTERED 12 0.0004
886 AGEUSIA 9 0.0004
887 RHABDOMYOLYSIS 15 0.0004
888 BRADYCARDIA 19 0.0004
889 COLITIS ULCERATIVE 16 0.0004
890 EYE PRURITUS 12 0.0004
891 PANIC ATTACK 13 0.0004
892 ARTHRITIS 28 0.0004
893 DISTURBANCE IN ATTENTION 19 0.0004
894 BLOOD PRESSURE ABNORMAL 7 0.0004
895 DYSGEUSIA 26 0.0003
896 FEEDING DISORDER 7 0.0003
897 NERVOUSNESS 18 0.0003
898 FLUSHING 35 0.0003
899 DEAFNESS 9 0.0003
900 SPEECH DISORDER 18 0.0003
901 DYSPHONIA 20 0.0003
902 NECK PAIN 19 0.0003
903 JOINT SWELLING 41 0.0003
904 ABDOMINAL PAIN UPPER 69 0.0003
905 THERAPEUTIC PRODUCT EFFECT DECREASED 15 0.0003
906 MEMORY IMPAIRMENT 46 0.0003
907 EYE DISORDER 11 0.0003
908 PAIN IN EXTREMITY 98 0.0003
909 CEREBRAL INFARCTION 8 0.0003
910 DRUG DOSE OMISSION 54 0.0003
911 INJECTION SITE SWELLING 25 0.0003
912 ABNORMAL DREAMS 9 0.0003
913 CHRONIC OBSTRUCTIVE PULMONARY DISEASE 17 0.0003
914 DYSPEPSIA 32 0.0003
915 FEMUR FRACTURE 10 0.0003
916 NERVOUS SYSTEM DISORDER 10 0.0003
917 SWOLLEN TONGUE 10 0.0003
918 AGGRESSION 16 0.0003
919 EYE PAIN 18 0.0003
920 PAIN IN JAW 9 0.0003
921 HAEMATEMESIS 8 0.0003
922 AGITATION 23 0.0003
923 CEREBROVASCULAR ACCIDENT 53 0.0003
924 ERECTILE DYSFUNCTION 8 0.0003
925 DISCOMFORT 19 0.0003
926 RHINORRHOEA 20 0.0003
927 DRY MOUTH 25 0.0003
928 THERAPY INTERRUPTED 22 0.0003
929 SURGERY 18 0.0003
930 JOINT STIFFNESS 8 0.0003
931 SEIZURE 35 0.0003
932 ABNORMAL BEHAVIOUR 12 0.0003
933 HYPERHIDROSIS 39 0.0003
934 CRYING 11 0.0003
935 BLOOD GLUCOSE INCREASED 57 0.0003
936 CARDIAC DISORDER 28 0.0003
937 PREMATURE BABY 9 0.0003
938 ARRHYTHMIA 14 0.0003
939 VERTIGO 18 0.0003
940 FOETAL EXPOSURE DURING PREGNANCY 24 0.0003
941 INJECTION SITE RASH 9 0.0003
942 THERAPY CESSATION 15 0.0003
943 LUNG NEOPLASM MALIGNANT 12 0.0003
944 INTESTINAL OBSTRUCTION 11 0.0003
945 RHEUMATOID ARTHRITIS 33 0.0003
946 PROCEDURAL PAIN 8 0.0003
947 INJECTION SITE BRUISING 23 0.0003
948 NEOPLASM PROGRESSION 10 0.0003
949 DEMENTIA 8 0.0003
950 INJURY 20 0.0003
951 DEATH 242 0.0003
952 HYPOACUSIS 12 0.0003
953 CARDIOVASCULAR DISORDER 7 0.0003
954 MYOCARDIAL INFARCTION 48 0.0003
955 DYSKINESIA 11 0.0003
956 MEDICATION ERROR 15 0.0003
957 PSORIASIS 35 0.0003
958 ADVERSE EVENT 24 0.0003
959 INJECTION SITE ERYTHEMA 32 0.0003
960 HEAD INJURY 8 0.0003
961 FEELING COLD 7 0.0003
962 ANGINA PECTORIS 7 0.0002
963 THERAPEUTIC RESPONSE SHORTENED 8 0.0002
964 ANGER 8 0.0002
965 HALLUCINATION 17 0.0002
966 NEOPLASM MALIGNANT 15 0.0002
967 ELECTROCARDIOGRAM QT PROLONGED 8 0.0002
968 PSORIATIC ARTHROPATHY 9 0.0002
969 RESTLESSNESS 8 0.0002
970 IRRITABILITY 13 0.0002
971 MATERNAL EXPOSURE DURING PREGNANCY 19 0.0002
972 INJECTION SITE PRURITUS 14 0.0002
973 MALIGNANT NEOPLASM PROGRESSION 20 0.0002
974 BLOOD GLUCOSE DECREASED 9 0.0002
975 EXTRA DOSE ADMINISTERED 7 0.0002
976 WRONG TECHNIQUE IN PRODUCT USAGE PROCESS 35 0.0002
977 DRUG EFFECT DECREASED 9 0.0002
978 DEVICE LEAKAGE 7 0.0002
979 INCORRECT DOSE ADMINISTERED 36 0.0002
980 HOT FLUSH 11 0.0001
981 DRUG DEPENDENCE 23 0.0001
982 OVERDOSE 30 0.0001
983 COMPLETED SUICIDE 11 0.0001
984 INJECTION SITE PAIN 39 0.0001
985 INJECTION SITE HAEMORRHAGE 10 0.0001
986 DEVICE MALFUNCTION 8 0.0001
987 ACCIDENTAL EXPOSURE TO PRODUCT 11 0.0001
988 BREAST CANCER 9 0.0001
989 PRODUCT STORAGE ERROR 8 0.0001
990 DEVICE ISSUE 7 0.0001